3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
3
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Tumor-Agnostic
3
Conditions
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Large-Cell, Anaplastic
2
Sexual Dysfunction, Physiological
1
Rare Tumor
1
Neuroblastoma
1
Lymphoma
1
Lung Diseases
1
Eunuchism
1
Erectile Dysfunction
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
pembrolizumab
47
Specimen Handling
29
Magnetic Resonance Spectroscopy
25
Biopsy
25
Radiosurgery
17
Gemcitabine
17
Nivolumab
15
Paclitaxel
14
Cyclophosphamide
13
Cisplatin
13
Carboplatin
13
Bevacizumab
12
Drug Therapy
11
Taxes
10
Radiotherapy
10
Oxaliplatin
10
Leucovorin
10
Irinotecan
10
Fluorouracil
10
Capecitabine
10
trastuzumab deruxtecan
8
fludarabine
8
Pemetrexed
8
Doxorubicin
8
Cetuximab
8
cemiplimab
7
abemaciclib
7
Trastuzumab
7
Fulvestrant
7
Docetaxel
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm Metastasis
×
alectinib
×
Clear all
NCT04116541
2026-04-24
MegaMOST
Centre Leon Berard
Phase 2
Recruiting
455 enrolled
NCT05525858
2025-04-27
KOSMOSII
Seoul National University Bundang Hospital
Recruiting
1,000 enrolled
NCT04817956
2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2
Recruiting
3,000 enrolled